What is Modulus Therapeutics?
Modulus Therapeutics operates at the intersection of synthetic biology and generative design, focusing on the mainstreaming of cell therapies for autoimmune conditions. By leveraging a sophisticated platform for crafting custom CARs and switch receptors, the company is pioneering the development of off-the-shelf CAR-NK therapies. This approach is designed to enhance therapeutic efficacy while significantly reducing the logistical and preparation burdens associated with current patient-specific treatments. By prioritizing safety and accessibility, Modulus Therapeutics is effectively positioning itself as a leader in the next wave of immune cell engineering, targeting a critical gap in the autoimmune therapeutic market.
How much funding has Modulus Therapeutics raised?
Modulus Therapeutics has raised a total of $3.5M across 1 funding round:
Angel/Seed
$3.5M
Angel/Seed (2021): $3.5M with participation from Ai2, Madrona Venture Group, and KdT Ventures
Key Investors in Modulus Therapeutics
Ai2
Ai2 is a specialized firm focused on medical device infection prevention, utilizing protein-based peptide coatings to enhance biocompatibility and clinical safety.
Madrona Venture Group
Established in 1995, Madrona Venture Group is a prominent venture capital firm with a diverse portfolio spanning consumer internet, commercial software, and high-growth services.
KdT Ventures
KdT Ventures is a venture capital firm specializing in early-stage frontier science, focusing on transformative technologies that engineer matter, energy, and information.
What's next for Modulus Therapeutics?
With the recent infusion of capital, Modulus Therapeutics is poised to scale its rapid prototyping capabilities and advance its lead candidates toward clinical trials. The strategic roadmap involves refining its generative design engine to optimize the performance of CAR-NK cells, ensuring they remain both potent and scalable for broader patient populations. As the company moves into this next phase of growth, the focus will shift toward establishing key partnerships with medical device manufacturers and clinical research organizations to streamline the delivery of these innovative therapies. Investors are closely monitoring the firm's ability to translate its platform's technical advantages into tangible, life-altering patient outcomes, which will be essential for securing future rounds of institutional financing.
See full Modulus Therapeutics company page
